| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 一种人尿激肽原酶粗制品的制备方法 | CN201611101691.X | 2016-12-02 | CN106754839A | 2017-05-31 | 王旭; 章华; 何建国; 曾永峰 |
| 本发明提供一种人尿激肽原酶粗制品的制备方法，包括如下步骤：收集吸附剂，洗脱，收集尿蛋白洗脱峰；进行超滤浓缩，调节pH为4～5.8，电导率为20～70mS/cm，得到浓缩液；上样金属螯合亲和层析柱，平衡液冲洗金属螯合亲和层析柱，然后使用水作为洗脱液进行洗脱，收集人尿激肽原酶洗脱峰；缓慢加入硫酸铵，搅拌，静置，收集沉淀，得到人尿激肽原酶粗制品。本发明属于色谱分离技术领域，本发明提高了人尿激肽原酶粗制品收率，降低了生产成本，获得的人尿激肽原酶粗制品产品质量好，KN比活高。 | ||||||
| 2 | 一种胰激肽原酶肠溶片及其工艺研究 | CN201611134808.4 | 2016-12-11 | CN106692958A | 2017-05-24 | 刘乃山; 路莹; 陈娥功 |
| 本发明公开了一种胰激肽原酶肠溶片工艺研究，技术方案是采用聚乙烯吡咯烷酮作为胰激肽原酶肠溶片的粘合剂，能得到崩解时间短的胰激肽原酶肠溶片，其处方如下（1000片）：胰激肽原酶18.5万单位；微晶纤维素50.0g；预胶化淀粉30.0g；乳糖90.0g；聚乙烯吡咯酮25ml；纯化水适量；硬脂酸镁0.5g。 | ||||||
| 3 | 一种疏水色谱纯化激肽释放酶的方法及含有激肽释放酶的药物组合物 | CN201410807834.3 | 2014-12-23 | CN104498461A | 2015-04-08 | 刘冠男; 林晓磊; 孙延年 |
| 本发明公开一种疏水色谱纯化激肽释放酶的方法及含有激肽释放酶的药物组合物，该方法通过以下工艺步骤：（1）离子交换层析;（2）盐析；（3）超滤；（4）热原处理；（5）透析；（6）疏水色谱；（7）冻干，制备激肽释放酶。本发明对激肽释放酶的生产工艺进行不断改进，特别是对各工艺参数进行反复的实验研究，不断优化，最终确立了一套更为科学的规模化生产工艺，经疏水色谱纯化所得的激肽释放酶的效价高达1500～1800iu/mg,并且各项指标均符合中国药典规定。 | ||||||
| 4 | 一种用醋酸提取激肽释放酶的方法 | CN201310638710.2 | 2013-11-29 | CN103740686A | 2014-04-23 | 刘乃山; 林晓磊; 李静洁; 刘君 |
| 本发明公开了一种用醋酸提取激肽释放酶的方法。本发明的技术方案是以猪胰为原料提取、沉淀猪胰制成丙酮粉后，灵活运用醋酸提取、丙酮沉淀，乙醚脱脂脱水等传统蛋白纯化技术，制备激肽释放酶。本发明操作简单，生产周期短，成本低廉，非常适用于规模化大生产。 | ||||||
| 5 | 人尿激肽原酶的新用途及含有人尿激肽原酶的药物组合物 | CN201611096335.3 | 2016-12-02 | CN106729661A | 2017-05-31 | 宋建东; 叶晓春; 孙明晖; 赵菁 |
| 本发明属于医药领域，具体涉及人尿激肽原酶的新用途及含有人尿激肽原酶的药物组合物。本发明提供的人尿激肽原酶在制备治疗特发性肺纤维化药物中的用途。本发明还提供了治疗特发性肺纤维化的药物组合物，该药物组合物包括人尿激肽原酶和盐酸艾司洛尔，还包括三七总皂苷，所述药物组合物可以显著降低特发性肺纤维化患者的肺系数和血清层粘连蛋白的含量，同时还可以有效的改善特发性肺纤维化患者肺部的损坏组织，延缓特发性肺纤维化的发病进程，大大改善特发性肺纤维化患者的生活质量，提高特发性肺纤维化患者治疗的顺应性，提高治疗效果，为特发性肺纤维化患者提供一种有效的治疗药物，大大的减轻特发性肺纤维化患者的痛苦。 | ||||||
| 6 | 一种从人尿中大规模收集尿蛋白的方法 | CN201611264697.9 | 2016-12-30 | CN106699876A | 2017-05-24 | 王旭; 李溪亭; 何建国 |
| 本发明涉及一种从人尿中收集尿蛋白的方法，特别适合于大规模使用，它是采用阴离子交换剂制作尿液过滤装置，将其置放于尿斗或小便槽内，用以承接尿液从过滤装置流过；尿液过滤装置的形状、大小与尿斗或小便槽相适应；定时回收尿液过滤装置，对其中的阴离子交换剂作集中解吸提取，提取收集含尿蛋白的组份，并对阴离子交换剂作再生处理备作再用。经后续的纯化处理，可制得各种指标均达到药典要求的尿蛋白，在多种领域作为人血浆来源白蛋白的替代品应用。更为重要的是该方法在吸附有尿蛋白的吸附剂处理之前，进行了相应的预处理，保证了尿蛋白的活性，减少了尿蛋白的降解和微生物的滋生，提高了尿蛋白产品的质量。 | ||||||
| 7 | 一种胰激肽原酶肠溶片的制备方法 | CN201611134810.1 | 2016-12-11 | CN106620671A | 2017-05-10 | 刘乃山; 宋姣姣; 陈娥功 |
| 本发明公开了一种胰激肽原酶肠溶片的制备方法，本发明的胰激肽原酶肠溶片由胰激肽原酶、微精纤维素、预胶化淀粉、羟丙甲基纤维素、药用乙醇、硬脂酸镁、褐藻胶包衣液、纯化水组成。本发明为肠溶片，可以使其在胃液中不溶解，在肠液中崩解溶化，发挥扩张血管，改善微循环的药效。该肠溶片无毒性，操作安全便利，质量稳定性好，符合胰激肽原酶肠溶片的技术要求。 | ||||||
| 8 | 一种胰激肽原酶的制备方法 | CN201510263121.X | 2015-05-21 | CN104830823A | 2015-08-12 | 刘盛儒; 王增鑫; 隗青; 孙岩; 王基伟; 张梅村; 迟创成 |
| 本发明公开了一种胰激肽原酶的制备方法，采用Amino acids-Sepharose亲和柱层析进行分离纯化，具体制备方法包括有平衡液和洗脱液的配制、平衡、进样、洗涤、洗脱、除菌、冻干等工序。制备的胰激肽原酶纯度高达95％以上，效价增加360单位/mg以上，比活达到920单位/mg蛋白以上，产品收率在90.0％以上，可直接作为注射剂的原料药进行应用。 | ||||||
| 9 | 一种规模化收集人尿蛋白的方法 | CN201310372615.2 | 2013-08-23 | CN103509104A | 2014-01-15 | 苗丕渠; 张纪兵; 苏古方; 俞恒; 许冬至 |
| 本发明公开了一种规模化收集人尿蛋白的方法。该方法包括如下步骤：将分装好的用于吸附尿蛋白的吸附剂放置在尿液流经处，使得吸附剂可以吸附尿液中的尿蛋白；收集吸附尿蛋白的吸附剂；并进行预处理；预处理后的吸附剂冷藏储存；批量运至加工厂进行尿蛋白解吸处理，生产相应的尿蛋白原料或尿蛋白制品。采用该技术方案收集人尿蛋白的方法，适合规模化、产业化生产尿蛋白，提高了尿蛋白的处理批量，减少了吸附剂的运输成本和尿蛋白的生产成本，在吸附有尿蛋白的吸附剂储存之前进行相应的预处理，保存了尿蛋白的活性，减少了尿蛋白的降解，减少了微生物的滋生，提高了尿蛋白产品的质量。 | ||||||
| 10 | METHODS AND MATERIALS FOR MODULATING RESISTANCE TO APOPTOSIS | US15584822 | 2017-05-02 | US20170296660A1 | 2017-10-19 | Isobel A. Scarisbrick |
| This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided. | ||||||
| 11 | Methods for modulating resistance to apoptosis using KLK6 | US13250599 | 2011-09-30 | US08530427B2 | 2013-09-10 | Isobel A. Scarisbrick |
| This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided. | ||||||
| 12 | METHODS TO REDUCE ADVERSE EVENTS CAUSED BY PHARMACEUTICAL PREPARATIONS COMPRISING PLASMA DERIVED PROTEINS | EP12719993.3 | 2012-05-14 | EP2707005B1 | 2017-08-23 | SCHULTE, Stefan; KALINA, Uwe; MOSES, Michael; FEUSSNER, Annette |
| The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction said plasma fraction comprising antithrombin III wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction. | ||||||
| 13 | Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins | EP11165869.6 | 2011-05-12 | EP2522354B1 | 2017-08-23 | Schulte, Stefan; Kalina, Uwe; Moses, Michael; Feussner, Annette |
| The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction said plasma fraction comprising antithrombin III wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction. | ||||||
| 14 | Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins | EP11165869.6 | 2011-05-12 | EP2522354A1 | 2012-11-14 | Schulte, Stefan; Kalina, Uwe; Moser, Michael; Feussner, Annette |
The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction said plasma fraction comprising antithrombin III wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction. |
||||||
| 15 | Methods for increasing susceptibility to apoptosis by administering an inhibitor of kallikrein 6 polypeptide activity | US13962686 | 2013-08-08 | US09669094B2 | 2017-06-06 | Isobel A. Scarisbrick |
| This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided. | ||||||
| 16 | METHODS AND MATERIALS FOR MODULATING RESISTANCE TO APOPTOSIS | US13962686 | 2013-08-08 | US20130315926A1 | 2013-11-28 | Isobel A. Scarisbrick |
| This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided. | ||||||
| 17 | METHODS AND MATERIALS FOR MODULATING RESISTANCE TO APOPTOSIS | US13250599 | 2011-09-30 | US20120093831A1 | 2012-04-19 | Isobel A. Scarisbrick |
| This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided. | ||||||
| 18 | TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE | US13055660 | 2009-07-24 | US20110150781A1 | 2011-06-23 | Matthew L. Charles; Mark Williams |
| The invention relates to methods of treating Parkinson's disease, dementia with Lewy bodies, and conditions associated with Parkinson's disease and dementia with Lewy bodies. Methods include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof. | ||||||
| 19 | METHODS TO REDUCE ADVERSE EVENTS CAUSED BY PHARMACEUTICAL PREPARATIONS COMPRISING PLASMA DERIVED PROTEINS | EP12719993.3 | 2012-05-14 | EP2707005A1 | 2014-03-19 | SCHULTE, Stefan; KALINA, Uwe; MOSES, Michael; FEUSSNER, Annette |
| The instant invention provides a method to reduce adverse events caused by a pharmaceutical preparation derived from a plasma fraction said plasma fraction comprising antithrombin III wherein the method comprises contacting the plasma fraction with heparin or a heparin-like substance thereby reducing the activity of at least one activated serine protease per ml of the plasma fraction. | ||||||
| 20 | TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE | EP09799910 | 2009-07-24 | EP2320939A4 | 2012-09-12 | CHARLES MATTHEW L; WILLIAMS MARK |
QQ群二维码
意见反馈
意见反馈